As GLP-1 adjuvants, MC4R-selective agonists are positioned as valuable therapeutics for both general and genetic obesity
According to NICE guidance (NG28), metformin remains the first-line pharmacological treatment for many people with type 2 diabetes in the UK, though SGLT2 inhibitors may be considered first-line in those with established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk
Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs)
Li S, Tan HY, Wang N, Zhang ZJ, Lao L, Wong CW, et al
Joint and Bone Health : BPC-157 promotes the healing of damaged joints, cartilage, and bones